Blue Jet Healthcare Ltd. Latest Updates

Quarterly Financial Results (Q1 FY26): The company reported a significant year-on-year growth in its financial performance for the quarter ended June 30, 2025. Revenue from operations grew by 117.8% year-on-year, primarily driven by higher sales in the Pharmaceutical Intermediates (PI) & Active Pharmaceutical Ingredients (API) product category. Net Profit after Tax (PAT) for the quarter also saw a substantial increase of 141.3% compared to the same quarter in the previous fiscal year. However, quarter-on-quarter, the revenue, EBITDA, and PAT saw a decline, mainly attributed to a drop in the gross margin due to a shift in the product mix and reduced inventory levels. Offer for Sale (OFS): A promoter, Akshay Bansarilal Arora, announced an Offer for Sale (OFS) of equity shares in September 2025, which included an over-subscription option. This action was taken for compliance with the minimum public shareholding requirements. Land Acquisition and Capex Plan: The company announced the acquisition of a large land parcel (102.48 acres) in Industrial Park Rambilli Cluster Phase II, Andhra Pradesh, for a high-impact greenfield site. The first phase of this expansion is planned to be a capacity build-out of up to ₹1,000 crore, to be funded through internal accruals, equity, and selective debt, and is scheduled to go live by FY 2028-29. This is intended to enable entry into new product verticals and deepen relationships in the Contract Development and Manufacturing Organization (CDMO) space. Corporate Governance and Awards: In September 2025, the company received the 'Excellent Energy Efficient Unit' award at the 26 th National Award for Excellence in Energy Management. Additionally, the Annual General Meeting (AGM) was held on September 26, 2025, with an outcome filed to the stock exchanges, and other routine compliances like the certificate under SEBI (DP) Regulations were filed in October 2025.